Investigating the effect of zinc nanoparticles on the transmission of HPV infection from a person infected with HPV virus

Investigating the effect of zinc nanoparticles on the transmission of HPV infection from a person infected with HPV virus

A clinical trial with two patient groups, parallel treatment, balanced block randomization, and double-blind (The researcher and the participant). 70 patients were referred to Sinai Hospital.

In the group of this clinical trial at Sina Hospital in Tehran, Urology Research Centre, double-blind (patient and researcher) Weber balanced block randomization will be performed on 70 patients. Patients are divided into two groups: The first group, the Human papillomavirus sample, is taken 5 minutes after using the ointment containing zinc oxide nanoparticles.Second, the human papillomavirus sample will be taken 5 minutes after the local application of the placebo ointment on the wart (this ointment does not contain any nanoparticles and is used only to prevent the distorting effect in the study).

Inclusion criteria: Men between the ages of 18 and 60 who have obvious warts، Obtaining informed consent from patients. Exclusion criteria: People who have received the Gardasil vaccine according to the previous indications.

Intervention group: human papillomavirus sample,5 minutes after using ointment containing zinc nanoparticles Control group: human papillomavirus sample, 5 minutes after topical application of placebo ointment on the wart (this ointment does not contain any nanoparticles and is used only to prevent the effect of confusion in the study).

Transmission of human papillomavirus

For randomization, the balanced block randomization method is used to generate blocks with size of 4. Intervention group A and control group B have been determined. According to the randomization method, we expect the two groups to differ by a maximum of 2 people in terms of the number of people assigned. After the methodologist prepares the randomization sequence using the Sealdenvelop online site, the generated sequence will be available to a technician outside the research team. blocks (A or B) are placed in envelopes. After the arrival of the first patient with the inclusion criteria, the envelopes are randomly selected, and the type of patient group is informed to the research team through a trained technician. Based on the randomly selected envelope, the patient is placed in the group (Double G plus placebo: 30 patients) or (Double G plus theophylline: 30 patients).

The present study is a double-blind, randomized clinical trial. The researcher and the participant will not know about the randomization method. The present study is a double-blind, randomized clinical trial study. The researcher and the participant will not know how to be placed in the control or intervention groups. In both groups, the same ointment made by Bonyakhte company is used. The first group is an ointment containing zinc oxide nanoparticles ، The Second group is a placebo ointment that does not contain any nanoparticles.

Demographic information anonymously

One year after publication

Researchers working in academia, physicians, surgeons and hospitals

Any analysis can be done with the consent of the main researcher

Sina Hospital, Urology Research Center, Head of Urology Research Center: Dr. Seyed Mohammad Kazem Aghamir 00982166348560 mkaghamir@tums.ac.ir

After reviewing the information by the administrator and epidemiologist, the patient information will be available for the applicant by the provision of a patient's privacy.